Because four positive lymph nodes were identified during surgery, the current standard of care is to recommend adjuvant chemotherapy for this patient. Some practitioners might also consider use of a gene expression profile or biomarker assay, although they are not validated in the setting of four or more positive lymph nodes.
Ki-67 is an indirect measure of cell proliferation. Although a high Ki-67 value is often considered a marker for poorer prognosis in early breast cancer, it cannot predict benefit of chemotherapy as a single measure. Recently, the International Ki67 in Breast Cancer Working Group concluded that "Ki67 has limited value for treatment decisions due to questionable analytical limitations." However, Ki-67 is included as part of the recurrence score, which can offer a broader evaluation of risks and benefits of adjuvant chemotherapy.
The androgen receptor has recently been studied as a potential marker of prognosis in some breast cancer subsets, as well as a potential therapeutic target. It has not, however, been identified as an indicator of adjuvant chemotherapy benefit.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Pavani Chalasani. Skill Checkup: A Menopausal Woman With a Lump in Her Right Breast - Medscape - Jan 18, 2022.
Comments